Tyrosine kinase inhibitors: Multi-targeted or single-targeted? - Test2 - elhamkhani - TriplyDB

Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

http://www.wikidata.org/entity/Q34983846

about

Comparative analysis and modeling of the severity of steatohepatitis in DDC-treated mouse strains Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?New perspectives in glioblastoma antiangiogenic therapy Profile of nintedanib in the treatment of solid tumors: the evidence to date ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study Targeting vascular endothelial growth factor receptor 2 and protein kinase D1 related pathways by a multiple kinase inhibitor in angiogenesis and inflammation related processes in vitro ALK-rearrangements and testing methods in non-small cell lung cancer: a review Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury Aurora kinases as druggable targets in pediatric leukemia: heterogeneity in target modulation activities and cytotoxicity by diverse novel therapeutic agents.Identification of a Mitochondrial DNA Polymerase Affecting Cardiotoxicity of Sunitinib Using a Genome-Wide Screening on S. pombe Deletion Library.Targeting angiogenesis in metastatic breast cancer Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma Pharmacological Modulation of the N-End Rule Pathway and Its Therapeutic Implications.Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily.Advanced medullary thyroid cancer: pathophysiology and management The protein kinase promiscuities in the cancer-preventive mechanisms of NSAIDs.Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy.Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer.Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology.Republished: Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology.Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.Innovative computer-aided methods for the discovery of new kinase ligands.Exploiting receptor tyrosine kinase co-activation for cancer therapy.Novel Approaches to Apoptosis-Inducing Therapies.Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.Progress in tumor-associated macrophage (TAM)-targeted therapeutics.PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells.Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells.Molecular dynamics and integrated pharmacophore-based identification of dual [Formula: see text] inhibitors.Cell death-based treatment of neuroblastoma.Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review.Development and validation of a micellar liquid chromatographic method to determine three antitumorals in plasma.Structural pliability adjacent to the kinase domain highlights contribution of FAK1 IDRs to cytoskeletal remodeling.Replica to K. Takeda et al. Commentary to Pastore et al. (2014): epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors.Radiobrominated benzimidazole-quinoline derivatives as Platelet-derived growth factor receptor beta (PDGFRβ) imaging probes.Imatinib Inhibits GH Secretion From Somatotropinomas Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies

P2860

Q21559453-09DE6507-F69B-429D-AE2B-6ABADFBA0ED3 Q26739760-5A973638-5CFA-4EC0-A511-7DC60FB6C6F3 Q26746028-A8B614D4-E071-4AAC-AD64-E6DB3F887034 Q26775134-9C8165AE-9563-42F4-9929-DD0EAD46B064 Q28289188-F9B0DFC9-943F-4158-AA75-DC81B1D89E04 Q28545130-E0FA7DC9-B589-4246-83A0-9336341C383D Q28546317-01589517-A102-4CDE-AD3B-A144122C6EC1 Q33776835-54BB6944-FA78-4248-AC1D-71378D2D35B4 Q35039202-9C1D4D2B-BB7B-42C9-830B-C01FFBC22297 Q35210664-BCCB3AAC-91A9-4E3F-9F27-0F5B466812D4 Q35781121-713F9E90-2A06-43C4-AE57-65347A5F12B0 Q36182795-A780A8E9-8D76-4983-948B-179748AC9C1E Q36244298-DE080DC3-9973-44FA-8782-FE352C2A2FA7 Q36269224-C6AFDF1D-2B36-43D6-8140-86705A4DF8F9 Q36280842-96C222B7-BF14-4DF8-9017-F690E2C59E14 Q36857218-ECDC135E-8F4B-4C8A-A712-280A3AB7EDD9 Q36947861-44EAA06B-4A1E-4332-BF01-0F3E2FEF4639 Q36962501-4951B20E-4125-43AC-B299-E36B5D895536 Q37723370-FAA29892-B73C-45AB-B3F0-BA7284A9A23D Q38095848-FD016094-D8A5-45AE-9185-AF5B97B6F5FF Q38167808-F599B554-E3D5-4908-BEF2-8F6C76F6A467 Q38241160-EEA38141-573F-4CE4-90CC-F2F066E3B965 Q38481540-B1687D0B-9642-402F-A2CE-7253824D0027 Q38757723-7E8A7354-6F9F-4C97-AE59-59F505585C53 Q38814898-843359F1-F201-4EB2-B4BA-034B33343835 Q38906990-C5E69EBA-CA9E-4865-B5E3-CD671FEDBEC7 Q38936710-1E4FCCF2-FAF0-416C-84ED-77B31B9298BE Q39008859-8B42E3A3-EB89-4864-8EEB-E02D3B214F3B Q39267549-BDA0432D-631D-4721-BC42-3BEAD29DEB6C Q41628138-FB786791-53E3-4A0C-99D0-21E5396975C1 Q47124737-47033A22-AE66-46D3-811D-F1BED98EC606 Q47401024-53119064-43C8-4164-A9E1-2657B3F11905 Q47839039-886C8F67-FEAB-4931-B49D-DD76ADBA25D5 Q49188770-20ABA625-517D-4C9B-AE53-77DF32EC17AB Q50638576-58EFB750-DE6E-4C70-8FD0-7669448ED0E2 Q51414693-6EFD29E3-849C-499D-BB30-861D3D4202BA Q54311709-CC69208A-3947-405A-99E8-72BC5D5A65F7 Q55655153-A995EB49-0927-4089-94D8-4CC33969B185 Q58633992-F49852CC-EAA2-45FD-ADD2-D3D732D93401 Q58739975-29805363-7D0A-4258-B8D2-17BDAC0EBDC4

P2860

Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

http://www.wikidata.org/entity/Q34983846

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

@ast

Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

@en

Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

@nl

type

label

Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

@ast

Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

@en

Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

@nl

prefLabel

Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

@ast

Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

@en

Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

@nl

P1433

Q34983846-78E1A6DE-CAE5-43B9-824B-5D75606CE359

P1476

Q34983846-48DB0670-0AAC-48B5-8A22-223AD999001F

P2093

Q34983846-3703192B-1393-4870-97B7-7C92454B16E9

Q34983846-711DB16B-51BE-4955-9A6F-A53E2F4241FE

Q34983846-F3B64D89-2411-49BC-AB7E-A529D0011AF3

P2860

Q34983846-061FAFA0-62D7-4F67-A678-061F91B0FA25

Q34983846-076796EB-D3F7-4B88-BF42-04D3907CCDCB

Q34983846-0D42649E-E6F9-49E4-8947-8C0DEE6959E2

Q34983846-0DE63BE8-AAFD-4548-9C67-16D96B949F66

Q34983846-102BEF1B-6A00-4C5C-93D6-0CD5387CD318

Q34983846-14DF23A9-62F3-437C-BE24-3FD6AF760D52

Q34983846-176CDAB9-4666-4756-AA9E-48DA314FDD16

Q34983846-18F14EA1-48D1-4894-ADE2-DDDDED35BD31

Q34983846-22508870-3D41-4134-9D91-77AC486EED90

Q34983846-23AC4077-A66B-4BD4-B978-2EDE721971AB

P304

Q34983846-133AD23A-B28E-45E0-B188-7C4EF609B83C

P31

Q34983846-62abf206-a17a-4d96-b6f0-c9726e84588d

Q34983846-DE1EAFDF-1BE3-4A1A-854C-D4DFEDEFB65E

P356

Q34983846-22CD2DCA-9E70-4A48-91DC-59D951454597

P433

Q34983846-8BE4B5E2-E564-4BA9-BC00-96D0CEB6B31F

P478

Q34983846-46B4CD52-93EB-4E2B-A7BD-8A5BC6B96B43

P577

Q34983846-4561D3BA-08A2-463A-B426-8A69F32A2D78

P5875

Q34983846-176B8B6D-900D-4C82-BAC1-D183F35E1B88

P698

Q34983846-44560746-0079-47FE-9EFC-290B18849114

P932

Q34983846-5BAD6C5A-D564-494E-A14A-9EB856E7BC3F

P356

P1433

World journal of clinical oncology

P1476

Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

@en

P2093

Elisa Giovannetti

http://www.w3.org/2001/XMLSchema#string

Fleur Broekman

http://www.w3.org/2001/XMLSchema#string

Godefridus J Peters

http://www.w3.org/2001/XMLSchema#string

P2860

The protein kinase complement of the human genome

Inflammation and cancer

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

Cell signaling by receptor tyrosine kinases

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

P304

80-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5306/WJCO.V2.I2.80

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51156897

http://www.w3.org/2001/XMLSchema#string

P698

21603317

http://www.w3.org/2001/XMLSchema#string

P932

3095472

http://www.w3.org/2001/XMLSchema#string